eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2018
vol. 13
 
Share:
Share:
abstract:
Original paper

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4

Dorota Kozielewicz
,
Anna Grabińska
,
Grzegorz Madej
,
Magdalena Wietlicka-Piszcz

Gastroenterology Rev 2018; 13 (1): 22–29
Online publish date: 2018/03/26
View full text Get citation
 
PlumX metrics:
Introduction
Dual therapy (PegIFN and ribavirin) (DT) was the standard of care in patients infected with HCV genotype 4 (HCV-4) until 2014. Nowadays, new treatment options are available including interferon (IFN)-based and other IFN-free regimens.

Aim
To assess the efficacy (SVR24) and safety of DT and the selected predictor factors of SVR in HCV-4 infected patients.

Material and methods
One hundred and twelve patients (62 men) of median age 23 years were treated with DT for 48/72 weeks (107/5) in the years 2006–2014. Most of them were treatment naïve (80.4%) and with fibrosis F ≤ 2 (83.1%). To select a subset of independent predictors of SVR Logistic Regression Analysis was applied.

Results
SVR24 was achieved in 46/112 (41.1%) patients. The mean viral load was 5.55 log10 IU/ml. Lack of therapy experience increases the odds of achieving SVR (OR = 4.17; 1.04–16.67), whereas more advanced fibrosis and higher baseline viral load tend to decrease the probability of SVR (OR = 0.05; 0.01–0.52 and OR = 0.44; 0.17–1.13, respectively). In contrast, the weight loss is associated with higher probability of virological response (OR = 4.31; 1.37–13.60). Two hundred and seventy-nine adverse events (AEs) were reported in 96 individuals. The rates and types of AEs were similar in patients treated with PegIFN-α2a/RBV and PegIFN-α2b/RBV. Overall, 3 (2.7%) patients discontinued therapy prematurely because of serious AEs.

Conclusions
SVR24 was low. Loss of weight was a new positive predictive factor of SVR found in our study. Most of the AEs were typical of those previously reported for DT.

keywords:

pegylated interferon, HCV genotype 4, sustained virological response

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.